Don't want to miss the best from Business Standard?
Astec Lifesciences announced that ICRA has reaffirmed/ assigned the long-term rating of [ICRA]AA- (pronounced 'ICRA double A minus') and the short term rating of [ICRA]A1+ (pronounced 'ICRA A one plus') for the Rs. 839 crore (enhanced from Rs.574 crore) Fund Based and Non-Fund Based facilities of the Company. Further, ICRA has revised the outlook on the long-term rating from 'Stable' to 'Positive'
Powered by Capital Market - Live News
Don't want to miss the best from Business Standard?
Disclaimer: No Business Standard Journalist was involved in creation of this content
